Literature DB >> 26860106

Combination Therapies for Melanoma: A New Standard of Care?

Keiran S M Smalley1,2, Zeynep Eroglu3, Vernon K Sondak3.   

Abstract

Recent data have demonstrated improved survival with targeted and immune therapies in patients with advanced melanoma, leading to much excitement amongst the oncology community and the widespread use of these drugs in combination regimens. However, the place of these combination therapies in the treatment of advanced melanoma remains to be fully determined. In this perspectives article, we critically review the available data and outline the rationale for these combinations being adopted as the standard of care for patients with advanced melanoma in the future.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26860106      PMCID： PMC4805442          DOI： 10.1007/s40257-016-0174-8

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN： 1175-0561            Impact factor:   7.403


  40 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

2.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

3.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Authors:  Axel Hauschild; Jean-Jacques Grob; Lev V Demidov; Thomas Jouary; Ralf Gutzmer; Michael Millward; Piotr Rutkowski; Christian U Blank; Wilson H Miller; Eckhart Kaempgen; Salvador Martín-Algarra; Boguslawa Karaszewska; Cornelia Mauch; Vanna Chiarion-Sileni; Anne-Marie Martin; Suzanne Swann; Patricia Haney; Beloo Mirakhur; Mary E Guckert; Vicki Goodman; Paul B Chapman
Journal:  Lancet       Date:  2012-06-25       Impact factor: 79.321

4.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors:  Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal:  N Engl J Med       Date:  2012-09-29       Impact factor: 91.245

5.  Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

Authors:  James S Wilmott; Georgina V Long; Julie R Howle; Lauren E Haydu; Raghwa N Sharma; John F Thompson; Richard F Kefford; Peter Hersey; Richard A Scolyer
Journal:  Clin Cancer Res       Date:  2011-12-12       Impact factor: 12.531

6.  Targeting oncogenic drivers and the immune system in melanoma.

Authors:  Grant A McArthur; Antoni Ribas
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

Review 7.  Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.

Authors:  Geoffrey T Gibney; Jane L Messina; Inna V Fedorenko; Vernon K Sondak; Keiran S M Smalley
Journal:  Nat Rev Clin Oncol       Date:  2013-05-28       Impact factor: 66.675

8.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.

Authors:  Mario Sznol; Lieping Chen
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531

10.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531
View more
  12 in total

Review 1.  New insights on the role of autophagy in the pathogenesis and treatment of melanoma.

Authors:  Marveh Rahmati; Shiva Ebrahim; Saadeh Hashemi; Masoumeh Motamedi; Mohammad Amin Moosavi
Journal:  Mol Biol Rep       Date:  2020-10-09       Impact factor: 2.316

2.  The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies.

Authors:  Mahamat Babagana; Julia V Kichina; Hannah Slabodkin; Sydney Johnson; Alexei Maslov; Lorin Brown; Kristopher Attwood; Mikhail A Nikiforov; Eugene S Kandel
Journal:  Mol Carcinog       Date:  2019-09-30       Impact factor: 4.784

3.  Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

Authors:  Daniel Verduzco; Brent M Kuenzi; Fumi Kinose; Vernon K Sondak; Zeynep Eroglu; Uwe Rix; Keiran S M Smalley
Journal:  Mol Cancer Ther       Date:  2017-11-13       Impact factor: 6.261

4.  Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy.

Authors:  Latifa Rbah-Vidal; Aurélien Vidal; Emilie M F Billaud; Sophie Besse; Isabelle Ranchon-Cole; Florence Mishellany; Yann Perrot; Lydia Maigne; Nicole Moins; Jean-Luc Guerquin-Kern; Françoise Degoul; Jean-Michel Chezal; Philippe Auzeloux; Elisabeth Miot-Noirault
Journal:  Neoplasia       Date:  2016-12-14       Impact factor: 5.715

5.  Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation.

Authors:  Luca Quattrini; Vito Coviello; Stefania Sartini; Teresa Di Desidero; Paola Orlandi; Yi-Yu Ke; Kai-Lun Liu; Hsing-Pang Hsieh; Guido Bocci; Concettina La Motta
Journal:  Sci Rep       Date:  2019-07-09       Impact factor: 4.379

Review 6.  Holistic view of patients with melanoma of the skin: how can health systems create value and achieve better clinical outcomes?

Authors:  Patrícia Redondo; Matilde Ribeiro; Machado Lopes; Marina Borges; Francisco Rocha Gonçalves
Journal:  Ecancermedicalscience       Date:  2019-08-27

7.  Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover.

Authors:  Celeste Lebbé; Caroline Dutriaux; Thierry Lesimple; Willem Kruit; Joseph Kerger; Luc Thomas; Bernard Guillot; Filippo de Braud; Claus Garbe; Jean-Jacques Grob; Carmen Loquai; Virginia Ferraresi; Caroline Robert; Paul Vasey; Robert Conry; Richard Isaacs; Enrique Espinosa; Armin Schueler; Giorgio Massimini; Brigitte Dréno
Journal:  Cancers (Basel)       Date:  2020-06-29       Impact factor: 6.639

Review 8.  Identification of an irreversible PPARγ antagonist with potent anticancer activity.

Authors:  Youyi Peng; Qiang Zhang; Robert M Zielinski; Richard D Howells; William J Welsh
Journal:  Pharmacol Res Perspect       Date:  2020-12

9.  Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model.

Authors:  Mariangela Garofalo; Laura Bertinato; Monika Staniszewska; Magdalena Wieczorek; Stefano Salmaso; Silke Schrom; Beate Rinner; Katarzyna Wanda Pancer; Lukasz Kuryk
Journal:  Pharmaceutics       Date:  2021-04-14       Impact factor: 6.321

10.  Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression.

Authors:  Berline Murekatete; Ali Shokoohmand; Jacqui McGovern; Lipsa Mohanty; Christoph Meinert; Brett G Hollier; Alfred Zippelius; Zee Upton; Abhishek S Kashyap
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.